



A Public Limited Company with Share Capital of 12,673,913.25 euros  
Registered Address 49, boulevard du Général Martial Valin – 75015 Paris  
Paris Trade and Companies' Register 410 910 095

## ***SUMMARY OF ONXEO'S LIQUIDITY CONTRACT WITH CM-CIC SECURITIES***

**January 8, 2018 – 5:45 pm CET**

Pursuant to the liquidity contract granted to CM-CIC SECURITIES regarding Onxeo shares, the following resources were listed in the liquidity account as at December 31, 2017, settlement date:

- 77,752 shares
- €49,516.66 in cash

As at June 30, 2017, the most recent update, the following resources had been allocated to the liquidity account:

- 13,829 shares
- €141,047.13 in cash

### **About Onxeo**

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a French biotechnology company developing innovative oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after mechanisms of action in cancer treatment today. The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

Onxeo's R&D pipeline includes **belinostat**, an HDAC inhibitor (epigenetics) currently being developed in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors. Belinostat is already conditionally FDA-approved in the US as a 2<sup>nd</sup> line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo's partner, Spectrum Pharmaceuticals, under the name Beleodaq® (belinostat IV form).

Onxeo is also developing **AsiDNA™**, a first-in-class DNA break repair inhibitor based on a unique decoy mechanism. AsiDNA™ has already successfully completed a Phase I trial in metastatic melanoma via local administration, and is currently being developed for systemic (IV) administration in solid tumors.

AsiDNA™ is the first compound generated from **platON™**, the Company's proprietary chemistry platform of decoy oligonucleotides based on three components, a sequence of double strand oligonucleotides, a linker and a cellular uptake facilitator. PlatON™ will continue to generate new compounds that will broaden Onxeo's pipeline.

**For further information, please visit [www.onxeo.com](http://www.onxeo.com).**

**Forward looking statements**

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 5.5.1.4 "Risk Factors" ("*Facteurs de Risque*") of the 2016 reference document filed with the *Autorité des marchés financiers* on April 24, 2017 under number D.17-0423, which is available on the *Autorité des marchés financiers* website ([www.amf-france.org](http://www.amf-france.org)) or on the Company's website ([www.onxeo.com](http://www.onxeo.com)).

**Onxeo**

Valerie Leroy,  
Investor Relations  
[investors@onxeo.com](mailto:investors@onxeo.com)  
+33 1 45 58 76 00

**Media Relations**

Caroline Carmagnol  
[alize-onxeo@alizerp.com](mailto:alize-onxeo@alizerp.com)  
+33 6 64 18 99 59

**Investor Relations / Strategic  
Communication**

Dušan Orešanský / Emmanuel Huynh  
NewCap  
[onxeo@newcap.eu](mailto:onxeo@newcap.eu)  
+33 1 44 71 94 92

**Investor Relations US**

Brian Ritchie  
LifeSci Advisors  
[britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)  
+1 212 915 2578